Merck’s Daily PCSK9 Pill: A Gamechanger for Hypercholesterolemia Patients? byMagallanes •April 13, 2023 Merck & Co is pushing forward with its Phase 3 program to test the efficacy of MK-0616, an oral cholesterol-lowering drug that has shown promise in mid-stage trials by matching the effects of approved injectable competitors. This developme…
